ストックスクリーナーアプリを入手
0.876
1.57%
-0.014
前日終値:
$0.89
開ける：
$0.9
24時間の取引高:
55,186
Relative Volume:
0.20
時価総額：
$14.36M
収益：
$19.91M
当期純損益:
$-127.11M
株価収益率:
-0.1039
EPS:
-8.428
ネットキャッシュフロー:
$-132.44M
1週間 パフォーマンス:
-11.52%
1か月 パフォーマンス:
-17.36%
6か月 パフォーマンス:
-78.10%
1年 パフォーマンス:
-81.71%
1日の値動き範囲:
$0.857
$0.9042
1週間の範囲:
$0.85
$1.03
52週間の値動き範囲:
$0.85
$8.95
Affimed N V Stock (AFMD) Company Profile
AFMD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AFMD
Affimed N V
|
0.876 | 14.36M | 19.91M | -127.11M | -132.44M | -8.428 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Affimed N V Stock (AFMD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-12-12 | 開始されました | H.C. Wainwright | Buy |
| 2022-10-10 | ダウングレード | Stifel | Buy → Hold |
| 2022-08-18 | 再開されました | Wells Fargo | Overweight |
| 2022-03-31 | 開始されました | Piper Sandler | Overweight |
| 2022-02-23 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-10-21 | 開始されました | Truist | Buy |
| 2021-09-30 | 開始されました | Stifel | Buy |
| 2021-03-31 | 開始されました | Credit Suisse | Outperform |
| 2019-03-28 | 開始されました | SVB Leerink | Outperform |
| 2018-08-28 | アップグレード | Jefferies | Hold → Buy |
| 2017-07-14 | 開始されました | SunTrust | Buy |
| 2016-08-12 | ダウングレード | Leerink Partners | Outperform → Mkt Perform |
| 2016-05-19 | ダウングレード | Leerink Partners | Outperform → Mkt Perform |
| 2015-12-10 | 開始されました | Laidlaw | Buy |
| 2015-12-04 | 開始されました | Wells Fargo | Outperform |
| 2015-09-09 | 開始されました | Jefferies | Hold |
| 2015-08-06 | 繰り返されました | Oppenheimer | Outperform |
| 2015-06-22 | 繰り返されました | Jefferies | Buy |
すべてを表示
Affimed N V (AFMD) 最新ニュース
Affimed at Leerink’s Conference: Clinical and Strategic Insights - Investing.com
Affimed at Leerink’s Conference: Clinical and Strategic Insights By Investing.com - Investing.com UK
Affimed N.V. to Host Earnings Call - ACCESS Newswire
Can Affimed's CEO Presentation Signal New Oncology Breakthroughs? Conference Watch - StockTitan
Affimed to Present at the Leerink Partners Global Healthcare Conference 2025 - The Manila Times
Affimed Announces Proposed Public Offering Of Common Stock - Reuters
Short Interest in Affimed (NASDAQ:AFMD) Declines By 12.3% - Defense World
Affimed (NASDAQ:AFMD) Stock Passes Below Two Hundred Day Moving Average – Here’s Why - Defense World
Jane Street Group LLC Acquires New Position in Affimed (NASDAQ:AFMD) - Defense World
Affimed (NASDAQ:AFMD) Sees Large Increase in Short Interest - Defense World
HC Wainwright Issues Positive Forecast for Affimed Earnings - Defense World
Equities Analysts Offer Predictions for Affimed Q1 Earnings - Defense World
Affimed Shares Fall 32% on Clinical Update - GuruFocus.com
Affimed stock plunges 23% on AFM24 study update - MSN
Affimed (NASDAQ:AFMD) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Affimed stock plunges 23% on AFM24 study update (AFMD:NASDAQ) - Seeking Alpha
Affimed’s Promising Clinical Update on NSCLC Treatment - TipRanks
Affimed Reports Positive Clinical Update on - GlobeNewswire
Affimed's AFM24 Trial Shows Promising 24% Response Rate in EGFR-Mutant Lung Cancer Patients - StockTitan
Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC) - Yahoo Finance
Affimed says 86% of patients responded to lymphoma therapy in mid-stage trial - MSN
Wells Fargo & Company Lowers Affimed (NASDAQ:AFMD) Price Target to $15.00 - Defense World
Affimed (NASDAQ:AFMD) Short Interest Update - Defense World
AFMD Stock Down Despite FDA's RMAT Status for Lymphoma Therapy - MSN
Affimed Reports Promising Phase 1 Efficacy and Safety Data - GlobeNewswire
Affimed Reports Promising Phase 1 Efficacy and Safety - One News Page
Affimed to Host Investor Conference Call Highlighting - GlobeNewswire
Affimed to Present AFM24 Lung Cancer Clinical Data in Conference Call - StockTitan
Affimed's Cancer Drug Achieves 86% Response Rate in Advanced Lymphoma Clinical Trial - StockTitan
Affimed Announces Positive Results Demonstrating Safety and - GlobeNewswire
Affimed Announces Pricing of Upsized $90 Million Public Offering of Common Shares - StockTitan
FDA RMAT status for Affimed and Artiva’s lymphoma combo therapy - Yahoo Finance
Affimed Announces Acimtamig and AlloNK® Combination Granted - GlobeNewswire
Affimed's Cancer Therapy Wins FDA RMAT Status After Striking 83% Response Rate in Lymphoma Trial - StockTitan
Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA) - Yahoo Finance
Affimed Q3 2024 Earnings Preview - MSN
Is Affimed N.V. (AFMD) the Best German Stock to Buy Now? - Insider Monkey
10 Best German Stocks To Buy Now - Insider Monkey
Affimed's (AFMD) "Overweight" Rating Reiterated at Cantor Fitzgerald - MarketBeat
Stifel Nicolaus Lowers Affimed (NASDAQ:AFMD) Price Target to $4.00 - Defense World
Affimed N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Stifel Nicolaus Cuts Affimed (NASDAQ:AFMD) Price Target to $4.00 - MarketBeat
Earnings call: Affimed reports promising results and strategic focus - Investing.com
Affimed N.V. (NASDAQ:AFMD) Q3 2024 Earnings Call Transcript - Insider Monkey
Affimed's (AFMD) Buy Rating Reiterated at HC Wainwright - MarketBeat
Affimed NV (AFMD) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges with ... - Yahoo Finance
Affimed NV (AFMD) Q3 2024 Earnings Call Highlights: Navigating F - GuruFocus.com
Affimed NV (AFMD) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges with ... By GuruFocus - Investing.com Canada
Affimed Reports Q3 2024 Financial Results and Updates - TipRanks
Affimed N.V.: Q3 Earnings Snapshot - Houston Chronicle
Affimed N V (AFMD) 財務データ
収益
当期純利益
現金流量
EPS
1.39%
0.55%
大文字化:
|
ボリューム (24 時間):